Costs of Type 1 Diabetes Acute and Chronic Complications in Brazil Private Healthcare System
Author(s)
Fernanda Laranjeira, PhD1, Igor Zanetti, MBA2;
1Medtronic PLC, Health Economics, Policy & Reimbursement Senior Manager, Sao Paulo, Brazil, 2Medtronic PLC, Market Access and Public Affairs, Sao Paulo, Brazil
1Medtronic PLC, Health Economics, Policy & Reimbursement Senior Manager, Sao Paulo, Brazil, 2Medtronic PLC, Market Access and Public Affairs, Sao Paulo, Brazil
OBJECTIVES: Type 1 diabetes (T1D) affects 0.27% of Brazilian population. In Brazil's private healthcare system, T1D patients are not eligible for treatment coverage, as it is categorized as home care. Although hospital costs for diabetes complications are covered, payers lack visibility of the true costs due to non-adequate disease management. This study reports T1D complications costs in Brazilian private healthcare system, based on secondary data.
METHODS: A narrative review was conducted to identify studies reporting costs of T1D acute and chronic complications in Brazil. The search was performed using Google Scholar and Medline via PubMed. Complications were searched individually, with no restrictions on date or language. For references published before 2024, cost adjustments based on Brazil's official inflation index (IPCA) were applied [initial IPCA value * (final month index / month prior to initial index)]. For studies reporting public healthcare costs, a conversion factor of 1.419 was used to estimate costs in private system. The conversion was based on two studies on stroke costs for both healthcare systems, conducted by the same research group and using the same methods.
RESULTS: The annual costs for T1D acute and chronic complications per person in Brazil, adjusted for 2024, are as follows: hypoglycemia R$5,238; ketoacidosis R$14,739; stroke R$167,087; heart failure R$31,613; heart attack R$26,093; peritoneal dialysis R$120,806; hemodialysis R$95,625; renal transplant (dead donator, 1st year) R$215,130; renal transplant (dead donator, 2nd+ year) R$21,871; neuropathy R$9,188; retinopathy R$10,435.
CONCLUSIONS: Spending on T1D complications is significant and is expected to increase further. Preventing acute and chronic complications relies on access to health care and adequate treatment. Innovative interventions for managing T1D are crucial in reducing acute and chronic complications and their associated costs, however, they are not currently covered by private insurance. Payors should reassess the value of homecare categorization for this patient population.
METHODS: A narrative review was conducted to identify studies reporting costs of T1D acute and chronic complications in Brazil. The search was performed using Google Scholar and Medline via PubMed. Complications were searched individually, with no restrictions on date or language. For references published before 2024, cost adjustments based on Brazil's official inflation index (IPCA) were applied [initial IPCA value * (final month index / month prior to initial index)]. For studies reporting public healthcare costs, a conversion factor of 1.419 was used to estimate costs in private system. The conversion was based on two studies on stroke costs for both healthcare systems, conducted by the same research group and using the same methods.
RESULTS: The annual costs for T1D acute and chronic complications per person in Brazil, adjusted for 2024, are as follows: hypoglycemia R$5,238; ketoacidosis R$14,739; stroke R$167,087; heart failure R$31,613; heart attack R$26,093; peritoneal dialysis R$120,806; hemodialysis R$95,625; renal transplant (dead donator, 1st year) R$215,130; renal transplant (dead donator, 2nd+ year) R$21,871; neuropathy R$9,188; retinopathy R$10,435.
CONCLUSIONS: Spending on T1D complications is significant and is expected to increase further. Preventing acute and chronic complications relies on access to health care and adequate treatment. Innovative interventions for managing T1D are crucial in reducing acute and chronic complications and their associated costs, however, they are not currently covered by private insurance. Payors should reassess the value of homecare categorization for this patient population.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE349
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Cardiovascular Disorders (including MI, Stroke, Circulatory), SDC: Diabetes/Endocrine/Metabolic Disorders (including obesity), SDC: Urinary/Kidney Disorders